U.S. FDA Approves Pfizer ’s Xeljanz (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis

NEW YORK--(BUSINESS WIRE) September 28, 2020 -- Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved Xeljanz® (tofacitinib) for the treatment of children and adolescents 2 years and...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news